SCHEMBL26655419

SCHEMBL26655419

CC1Cc2c(N3CCC(N4CCN(C)CC4)CC3)ccc(N)c2O1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.39
KDM4E B2RXH2 3/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
RECQL P46063 1/20 0.39
PTK2B Q14289 1/20 0.39
PARP1 P09874 1/20 0.38
ADRA2C P18825 1/20 0.35
ALDH1A1 P00352 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
POLB P06746 1/20 0.35
ACVR1 Q04771 2/20 0.35
VCP P55072 1/20 0.34
FGFR3 P22607 2/20 0.34
L3MBTL3 Q96JM7 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
KMT2A Q03164 1/20 0.34
PIM1 P11309 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26655460 0.81 MEN1 (0.43) GAAKDM4EMAPTMAPK1HTT
SCHEMBL24327352 0.80 POLB (0.41) GAAKDM4EMAPTMAPK1HTT
SCHEMBL29661314 0.80 KDM4E (0.38) GAAKDM4EMAPTMAPK1HTT
SCHEMBL24327660 0.80 KDM4E (0.38) GAAKDM4EMAPTMAPK1HTT
SCHEMBL24328563 0.79 PARP1 (0.40) GAAKDM4EMAPTMAPK1HTT
SCHEMBL29661326 0.79 PARP1 (0.40) GAAKDM4EMAPTMAPK1HTT
SCHEMBL24328518 0.76 ALDH1A1 (0.40) GAAKDM4EMAPTMAPK1HTT
SCHEMBL30206323 0.74 ALDH1A1 (0.47) GAAKDM4EMAPTMAPK1HTT
SCHEMBL24107836 0.74 ALDH1A1 (0.47) GAAKDM4EMAPTMAPK1HTT
SCHEMBL24327351 0.74 CARM1 (0.36) GAAKDM4EMAPTHTTPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
EP-4217348-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BeiGene, Ltd. (KY) 2023-08-02 EP disclosed
CN-116249690-A Indoline compounds and derivatives as EGFR inhibitors 百济神州有限公司 2023-06-09 CN disclosed
WO-2022063106-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEIGENE, LTD. (KY) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 GAA 3025/4885KDM4E 2783/4885MAPT 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.